568 related articles for article (PubMed ID: 31175052)
1. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
2. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
3. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
4. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
5. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
7. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.
Basser RL; Abraham R; To LB; Fox RM; Green MD
Ann Oncol; 1999 Jan; 10(1):53-8. PubMed ID: 10076722
[TBL] [Abstract][Full Text] [Related]
8. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Gil-Gil MJ; Bellet M; Morales S; Ojeda B; Manso L; Mesia C; Garcia-Martínez E; Martinez-Jáñez N; Melé M; Llombart A; Pernas S; Villagrasa P; Blasco C; Baselga J
Breast Cancer Res Treat; 2015 Jun; 151(3):597-606. PubMed ID: 25981896
[TBL] [Abstract][Full Text] [Related]
10. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
Hao W; Liu S; Qin Y; Sun C; Chen L; Wu C; Bao Y
Trials; 2017 Aug; 18(1):386. PubMed ID: 28830541
[TBL] [Abstract][Full Text] [Related]
12. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
[TBL] [Abstract][Full Text] [Related]
13. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
[TBL] [Abstract][Full Text] [Related]
14. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
15. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
[TBL] [Abstract][Full Text] [Related]
16. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
18. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
19. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
